{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T07:47:01Z","timestamp":1791013621687,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.biopha.2012.10.006","type":"journal-article","created":{"date-parts":[[2012,11,15]],"date-time":"2012-11-15T16:32:34Z","timestamp":1352997154000},"page":"39-42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Calcium channel blockers reduce oxaliplatin-induced acute neuropathy: A retrospective study of 69 male patients receiving modified FOLFOX6 therapy"],"prefix":"10.1016","volume":"67","author":[{"given":"Yoko","family":"Tatsushima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuaki","family":"Egashira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Narishige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiori","family":"Fukui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiro","family":"Kawashiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yui","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryozo","family":"Oishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2012.10.006_bib0005","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.critrevonc.2006.01.001","article-title":"Oxaliplatin-related neurotoxicity: how and why?","volume":"59","author":"Pasetto","year":"2006","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.biopha.2012.10.006_bib0010","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/PL00007853","article-title":"Chemotherapy-induced peripheral neuropathy","volume":"249","author":"Quasthoff","year":"2002","journal-title":"J Neurol"},{"key":"10.1016\/j.biopha.2012.10.006_bib0015","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1200\/JCO.2002.07.056","article-title":"Acute oxaliplatin-induced peripheral nerve hyperexcitability","volume":"20","author":"Wilson","year":"2002","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.biopha.2012.10.006_bib0020","first-page":"S38","article-title":"Clinical management of oxaliplatin-associated neurotoxicity","volume":"5","author":"Grothey","year":"2005","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.biopha.2012.10.006_bib0025","first-page":"13","article-title":"Pharmacokinetics and safety profile of oxaliplatin","volume":"25","author":"Extra","year":"1998","journal-title":"Semin Oncol"},{"key":"10.1016\/j.biopha.2012.10.006_bib0030","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1179\/joc.2004.16.6.595","article-title":"Dysphonia as an unusual toxic event of oxaliplatin-based chemotherapy","volume":"16","author":"Berretta","year":"2004","journal-title":"J Chemother"},{"key":"10.1016\/j.biopha.2012.10.006_bib0035","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","article-title":"Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer","volume":"18","author":"de Gramont","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.biopha.2012.10.006_bib0040","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1186\/1471-2407-10-451","article-title":"Detecting acute neurotoxicity during platinum chemotherapy by neurophysiological assessment of motor nerve hyperexcitability","volume":"10","author":"Hill","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.biopha.2012.10.006_bib0045","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ejpain.2010.08.006","article-title":"Prevention of oxaliplatin-induced mechanical allodynia and neurodegeneration by neurotropin in the rat model","volume":"15","author":"Kawashiri","year":"2011","journal-title":"Eur J Pain"},{"key":"10.1016\/j.biopha.2012.10.006_bib0050","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0014-2999(00)00667-1","article-title":"The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons","volume":"406","author":"Adelsberger","year":"2000","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.biopha.2012.10.006_bib0055","first-page":"263","article-title":"Oxaliplatin, an anticancer agent that affects both Na+ and K+ channels in frog peripheral myelinated axons","volume":"25","author":"Benoit","year":"2006","journal-title":"Gen Physiol Biophys"},{"key":"10.1016\/j.biopha.2012.10.006_bib0060","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1152\/jn.2001.85.5.2293","article-title":"A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels","volume":"85","author":"Grolleau","year":"2001","journal-title":"J Neurophysiol"},{"key":"10.1016\/j.biopha.2012.10.006_bib0065","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.neuro.2008.09.005","article-title":"The effects of oxaliplatin, an anticancer drug, on potassium channels of the peripheral myelinated nerve fibres of the adult rat","volume":"29","author":"Kagiava","year":"2008","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.biopha.2012.10.006_bib0070","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1200\/JCO.2010.31.5911","article-title":"Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7","volume":"29","author":"Grothey","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.biopha.2012.10.006_bib0075","first-page":"289","article-title":"Role of calcium\/magnesium infusion in oxaliplatin-based chemotherapy for colorectal cancer patients","volume":"24","author":"Kurniali","year":"2010","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.biopha.2012.10.006_bib0080","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.pain.2007.08.033","article-title":"Pharmacologic management of neuropathic pain: evidence-based recommendations","volume":"132","author":"Dworkin","year":"2007","journal-title":"Pain"},{"key":"10.1016\/j.biopha.2012.10.006_bib0085","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1002\/cncr.23008","article-title":"Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3)","volume":"110","author":"Rao","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.biopha.2012.10.006_bib0090","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.pain.2009.09.003","article-title":"Oxaliplatin-induced neuropathy in the rat: involvement of oxalate in cold hyperalgesia but not mechanical allodynia","volume":"147","author":"Sakurai","year":"2009","journal-title":"Pain"},{"key":"10.1016\/j.biopha.2012.10.006_bib0095","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.neulet.2009.04.029","article-title":"Involvement of increased expression of transient receptor potential melastatin 8 in oxaliplatin-induced cold allodynia in mice","volume":"458","author":"Gauchan","year":"2009","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.biopha.2012.10.006_bib0100","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/nature719","article-title":"Identification of a cold receptor reveals a general role for TRP channels in thermosensation","volume":"416","author":"McKemy","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2012.10.006_bib0105","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0092-8674(02)00652-9","article-title":"A TRP channel that senses cold stimuli and menthol","volume":"108","author":"Peier","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2012.10.006_bib0110","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1744-8069-8-7","article-title":"L type Ca2+ channel blockers prevent oxaliplatin-induced cold hyperalgesia and TRPM8 overexpression in rats","volume":"8","author":"Kawashiri","year":"2012","journal-title":"Mol Pain"},{"issue":"Suppl 1","key":"10.1016\/j.biopha.2012.10.006_bib0115","first-page":"S38","article-title":"Clinical management of oxaliplatin-associated neurotoxicity","volume":"5","author":"Grothey","year":"2005","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.biopha.2012.10.006_bib0120","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s10147-010-0183-1","article-title":"The Kampo medicine, Goshajinkigan, prevents neuropathy in patients treated by FOLFOX regimen","volume":"16","author":"Nishioka","year":"2011","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.biopha.2012.10.006_bib0125","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0304-3959(03)00160-X","article-title":"Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy","volume":"105","author":"Watson","year":"2003","journal-title":"Pain"},{"key":"10.1016\/j.biopha.2012.10.006_bib0130","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0303-8467(92)90066-C","article-title":"Effects of methylcobalamin on diabetic neuropathy","volume":"94","author":"Yaqub","year":"1992","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.biopha.2012.10.006_bib0135","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1345\/aph.1E319","article-title":"Oxaliplatin-associated neuropathy: a review","volume":"39","author":"Cersosimo","year":"2005","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.biopha.2012.10.006_bib0140","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1002\/1097-0142(19841001)54:7<1269::AID-CNCR2820540707>3.0.CO;2-9","article-title":"Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies","volume":"54","author":"Thompson","year":"1984","journal-title":"Cancer"},{"key":"10.1016\/j.biopha.2012.10.006_bib0145","first-page":"1205","article-title":"Clinical pharmacokinetics of oxaliplatin: a critical review","volume":"6","author":"Graham","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.biopha.2012.10.006_bib0150","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1158\/1078-0432.CCR-03-0666","article-title":"Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer","volume":"10","author":"Gamelin","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.biopha.2012.10.006_bib0155","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1017\/S0140525X97221485","article-title":"Sex differences in pain","volume":"20","author":"Berkley","year":"1997","journal-title":"Behav Brain Sci"},{"key":"10.1016\/j.biopha.2012.10.006_bib0160","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1200\/JCO.2006.06.9039","article-title":"Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil\/leucovorin administered bimonthly in elderly patients with colorectal cancer","volume":"24","author":"Goldberg","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.biopha.2012.10.006_bib0165","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/1756-9966-28-109","article-title":"Multicenter safety study of mFOLFOX6 for unresectable advanced\/recurrent colorectal cancer in elderly patients","volume":"28","author":"Sugimoto","year":"2009","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.biopha.2012.10.006_bib0170","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2165\/11590180-000000000-00000","article-title":"Bevacizumab-induced hypertension: pathogenesis and management","volume":"25","author":"Syrigos","year":"2011","journal-title":"BioDrugs"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332212000984?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332212000984?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T10:51:39Z","timestamp":1760093499000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332212000984"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S0753332212000984"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2012.10.006","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Calcium channel blockers reduce oxaliplatin-induced acute neuropathy: A retrospective study of 69 male patients receiving modified FOLFOX6 therapy","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2012.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}